HK Stock Movement | INNOVENT BIO (01801) Plunges Over 6% with Block Trades Worth Over HK$1.2 Billion Pre-Market

Stock News12-08

INNOVENT BIO (01801) saw a sharp decline of over 6%, dropping 5.43% to HK$87 by the time of writing, with a trading volume of HK$1.86 billion. The company successfully included seven innovative products (including new indications) in the latest national medical insurance catalog. Among them is the expanded indication for its PD-1 inhibitor, Tyvyt (sintilimab injection), with all eight approved indications now covered by insurance. The list also features several newly launched drugs targeting oncology and chronic diseases. Notably, INNOVENT BIO recently completed a strategic investment from Takeda Pharmaceutical, issuing 6.9138 million shares (approximately 0.4% of issued share capital) for a net proceeds of around HK$780 million. Additionally, pre-market block trades involved approximately 13.0734 million shares at an average price of HK$92 per share, totaling over HK$1.2 billion.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1119171968?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-08 10:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1119171968","market":"fut","top_or_hot":-1,"title":"HK Stock Movement | INNOVENT BIO (01801) Plunges Over 6% with Block Trades Worth Over HK$1.2 Billion Pre-Market","media":"Stock News","content":"<p>INNOVENT BIO (01801) saw a sharp decline of over 6%, dropping 5.43% to HK$87 by the time of writing, with a trading volume of HK$1.86 billion. The company successfully included seven innovative products (including new indications) in the latest national medical insurance catalog. Among them is the expanded indication for its PD-1 inhibitor, Tyvyt (sintilimab injection), with all eight approved indications now covered by insurance. The list also features several newly launched drugs targeting oncology and chronic diseases. Notably, INNOVENT BIO recently completed a strategic investment from Takeda Pharmaceutical, issuing 6.9138 million shares (approximately 0.4% of issued share capital) for a net proceeds of around HK$780 million. Additionally, pre-market block trades involved approximately 13.0734 million shares at an average price of HK$92 per share, totaling over HK$1.2 billion.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HK Stock Movement | INNOVENT BIO (01801) Plunges Over 6% with Block Trades Worth Over HK$1.2 Billion Pre-Market</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHK Stock Movement | INNOVENT BIO (01801) Plunges Over 6% with Block Trades Worth Over HK$1.2 Billion Pre-Market\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-12-08 10:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>INNOVENT BIO (01801) saw a sharp decline of over 6%, dropping 5.43% to HK$87 by the time of writing, with a trading volume of HK$1.86 billion. The company successfully included seven innovative products (including new indications) in the latest national medical insurance catalog. Among them is the expanded indication for its PD-1 inhibitor, Tyvyt (sintilimab injection), with all eight approved indications now covered by insurance. The list also features several newly launched drugs targeting oncology and chronic diseases. Notably, INNOVENT BIO recently completed a strategic investment from Takeda Pharmaceutical, issuing 6.9138 million shares (approximately 0.4% of issued share capital) for a net proceeds of around HK$780 million. Additionally, pre-market block trades involved approximately 13.0734 million shares at an average price of HK$92 per share, totaling over HK$1.2 billion.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1589","symbol_name":"北水核心资产","start_time":0,"source_url":"","article_id":"1119171968","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1119171968","pubTimestamp":1765159575,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"INNOVENT BIO (01801) saw a sharp decline of over 6%, dropping 5.43% to HK$87 by the time of writing, with a trading volume of HK$1.86 billion. The company successfully included seven innovative...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1589":"北水核心资产","LU2097828714.EUR":"AZ EQUITY CHINA \"BAZ\" (EUR) ACC","LU2097828474.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC A","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","LU2097828557.USD":"AZ EQUITY CHINA \"A\" (USD) ACC","LU0455707207.USD":"FIDELITY FUNDS  CHINA INNOVATION \"A\" (USD) INC","BK1583":"高瓴概念","LU2097828805.USD":"AZ EQUITY CHINA \"A-AZ\" (USD) ACC","BK1161":"生物科技","LU2242644610.SGD":"Fidelity China Innovation A-ACC-SGD","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","LU2097828631.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC","01801":"信达生物","LU0502904849.HKD":"FIDELITY FUNDS  CHINA INNOVATION \"A\" (HKD) ACC","HK0000165453.HKD":"华夏精选大中华科技基金 A类港币"},"translate_title":"港股动向|信达生物(01801)跌超6%盘前大宗交易涉超12亿港元","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01801":1},"content_text":"INNOVENT BIO (01801) saw a sharp decline of over 6%, dropping 5.43% to HK$87 by the time of writing, with a trading volume of HK$1.86 billion. The company successfully included seven innovative products (including new indications) in the latest national medical insurance catalog. Among them is the expanded indication for its PD-1 inhibitor, Tyvyt (sintilimab injection), with all eight approved indications now covered by insurance. The list also features several newly launched drugs targeting oncology and chronic diseases. Notably, INNOVENT BIO recently completed a strategic investment from Takeda Pharmaceutical, issuing 6.9138 million shares (approximately 0.4% of issued share capital) for a net proceeds of around HK$780 million. Additionally, pre-market block trades involved approximately 13.0734 million shares at an average price of HK$92 per share, totaling over HK$1.2 billion.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1119171968","isCrawlerRequest":true}